"""
Question: 1101 

Evidence: We examined Ugandan viruses from newly infected patients and focused on the contribution of the Gag-Pol genes to replication capacity. The Gag-Pol sequences described here have been deposited in GenBank with the accession numbers MT027065-MT027082, MW316895-MW316901, MW316906-MW316908, MW316914, MW316916, MW316920 and MW316924.

Rationale: The study describes new laboratory work generating and analyzing Gag-Pol sequences from early infections and provides newly assigned GenBank accession numbers, indicating previously unpublished primary data.

Answer: Yes
"""

"""
Question: 1102 

Evidence: Thirty-two Ugandan protocol C participants had sequences successfully cloned from early samples drawn within 90 days of EDI and had their VRC characterized. The Gag-Pol sequences described here have been deposited in GenBank with the accession numbers MT027065-MT027082, MW316895-MW316901, MW316906-MW316908, MW316914, MW316916, MW316920 and MW316924.

Rationale: The paper explicitly states that sequences were obtained and deposited in GenBank, confirming that HIV sequences were reported.

Answer: Yes
"""

"""
Question: 1103 

Evidence: To assess the VRC of Gag-Pol NL4.3 chimeras, 5 × 10^5 GXR25 cells were infected at a multiplicity of infection (MOI) of 0.05. The optimal window for logarithmic growth was determined to be between days 2--6.

Rationale: The methods describe single-cycle/multi-cycle replication assays over a short period to measure replication capacity, not serial in vitro passaging experiments aimed at adaptation or selection.

Answer: No
"""

"""
Question: 1104 

Evidence: To assess the VRC of Gag-Pol NL4.3 chimeras, 5 × 10^5 GXR25 cells were infected at a multiplicity of infection (MOI) of 0.05. Replication capacity values were generated by dividing the area under the curve (AUC) for days 2--6 of the chimeric viruses by the AUC of the NL4.3 wildtype after subtracting the negative control.

Rationale: The study measured replication capacity using growth curves and RT output; it did not test susceptibility to antiretroviral drugs or report IC values.

Answer: No
"""

"""
Question: 2101 

Evidence: The Gag-Pol sequences described here have been deposited in GenBank with the accession numbers MT027065-MT027082, MW316895-MW316901, MW316906-MW316908, MW316914, MW316916, MW316920 and MW316924. Data are available in GenBank (see Section 2.7).

Rationale: The paper provides explicit GenBank accession numbers for the sequences.

Answer: Yes
"""

"""
Question: 2102 

Evidence: Thirty-two Ugandan protocol C participants had sequences successfully cloned from early samples drawn within 90 days of EDI and had their VRC characterized. The Gag-Pol sequences described here have been deposited in GenBank with the accession numbers MT027065-MT027082, MW316895-MW316901, MW316906-MW316908, MW316914, MW316916, MW316920 and MW316924.

Rationale: The sequences are derived from clinical samples from newly infected Ugandan participants, not laboratory strains, and have associated GenBank accessions.

Answer: Yes
"""

"""
Question: 2103 

Evidence: The Gag-Pol sequences described here have been deposited in GenBank with the accession numbers MT027065-MT027082, MW316895-MW316901, MW316906-MW316908, MW316914, MW316916, MW316920 and MW316924. Data are available in GenBank (see Section 2.7).

Rationale: The paper lists specific accession numbers for all deposited sequences.

Answer: MT027065-MT027082; MW316895-MW316901; MW316906-MW316908; MW316914; MW316916; MW316920; MW316924
"""

"""
Question: 2202 

Evidence: Using a novel protein domain approach, we then documented diversity in the functional protein domains across the Gag-Pol region and identified differences in the Gag-p6 domain that were frequently associated with higher in vitro replication. A sequence logo of the Gag protein alignment shows the positions and residues unique to the low VRC sequences.

Rationale: The paper summarizes sequence variation using domain analysis and sequence logos rather than providing isolate-by-isolate mutation lists.

Answer: No
"""

"""
Question: 2301 

Evidence: HIV-1  Gag-Pol  Sequences from Ugandan Early Infections Reveal Sequence Variants Associated with Elevated Replication Capacity. During early HIV-1 infection, viremia increases rapidly, reaching a peak within weeks of infection, then drops to a level (the set point viral load or SPVL) that can remain stable over months to years of asymptomatic infection.

Rationale: The title and introduction specify the species studied is HIV-1.

Answer: HIV-1
"""

"""
Question: 2302 

Evidence: We observed 6 with subtype A1, 13 with subtype D and 13 inter-subtype recombinants. The recombinants identified were A1D (10), A1C (1), CD (1) and a complex recombinant of subtypes E, F1, G and A (1) ( Table 1 , Figure 1 ).

Rationale: The results enumerate the subtypes and recombinant forms detected among the sequenced viruses.

Answer: A1, D, A1D, A1C, CD, and a complex recombinant of E/F1/G/A (including 01AE as shown in Table 1).
"""

"""
Question: 2303 

Evidence: Using a reverse primer 5FIV-R1 (5′-CTYTTTCTCCTGTATGCAGACCCC-3′; nucleotides 5272 to 5249 of the HXB2 sequence), cDNA was generated that served as a template to amplify a 5 kb 5′ half viral genome fragment spanning the Gag-Pol region. We examined Ugandan viruses from newly infected patients and focused on the contribution of the Gag-Pol genes to replication capacity.

Rationale: The amplified and sequenced region is explicitly stated to span the Gag-Pol region.

Answer: Gag and Pol (Gag-Pol region)
"""

"""
Question: 2304 

Evidence: We examined Ugandan viruses from newly infected patients and focused on the contribution of the Gag-Pol genes to replication capacity. The 13 domains from the HIV-1 Gag-Pol region are described by Pfam, and preliminary results showed that seven domains (DUF935, zf-CCHC_2, Gag-P6 in the gag protein and gag_asp_proteas, RVT_thumb, integrase_Zn, rve_3 in the Pol protein, marked in green and orange in Figure 4 A) showed variation in the set of 32 sequences ( Figure 4 B).

Rationale: Since Pol is part of Gag-Pol and its domains were analyzed, the paper reports results from HIV pol sequences.

Answer: Yes
"""

"""
Question: 2401 

Evidence: We examined Ugandan viruses from newly infected patients and focused on the contribution of the Gag-Pol genes to replication capacity. This study utilized protocol C stored plasma samples from 60 participants within 90 days post-EDI.

Rationale: The sequences were derived from Ugandan participants, indicating the country/region of origin.

Answer: Uganda (East Africa)
"""

"""
Question: 2402 

Evidence: The samples were obtained in 2006–2011 and HIV-1 evolution has continued. However, the global analysis shown in Figure 5 included more recent sequence data up to December 2019 and the Gag-p6 variations we observed in the set of 32 early infection sequences appeared to be representative of the entire HIV-1 epidemic.

Rationale: The discussion states the collection years for the study samples.

Answer: 2006–2011
"""

"""
Question: 2502 

Evidence: 8--10 SGA amplicons were generated per patient and these were sequenced using di-deoxy sequencing technology (Applied Biosystems 3500), aligned and analyzed using Sequencher and Geneious software to infer an early infection consensus sequence. For single genome amplification (SGA), the cDNA was serially diluted in replicates of eight and subjected to nested PCR amplification with HIV-specific primers.

Rationale: Di-deoxy sequencing is Sanger sequencing, indicating the method used.

Answer: Yes
"""

"""
Question: 2503 

Evidence: 8--10 SGA amplicons were generated per patient and these were sequenced using di-deoxy sequencing technology (Applied Biosystems 3500), aligned and analyzed using Sequencher and Geneious software to infer an early infection consensus sequence. Using a reverse primer 5FIV-R1 ..., cDNA was generated that served as a template to amplify a 5 kb 5′ half viral genome fragment spanning the Gag-Pol region.

Rationale: The sequencing method was Sanger (di-deoxy), with no mention of next-generation sequencing.

Answer: No
"""

"""
Question: 2504 

Evidence: 8--10 SGA amplicons were generated per patient and these were sequenced using di-deoxy sequencing technology (Applied Biosystems 3500), aligned and analyzed using Sequencher and Geneious software to infer an early infection consensus sequence. The Gag-Pol amplicons were re-amplified with nested PCR ... and cloned into an NL4.3 provirus backbone using the infusion homologous recombination method.

Rationale: Sequencing was performed directly on SGA amplicons; cloning was done afterward for functional chimeras, not prior to sequencing.

Answer: No
"""

"""
Question: 2505 

Evidence: For single genome amplification (SGA), the cDNA was serially diluted in replicates of eight and subjected to nested PCR amplification with HIV-specific primers. 8--10 SGA amplicons were generated per patient and these were sequenced using di-deoxy sequencing technology (Applied Biosystems 3500).

Rationale: The methods explicitly describe single genome amplification followed by sequencing.

Answer: Yes
"""

"""
Question: 2506 

Evidence: The Gag-Pol amplicons were re-amplified with nested PCR with primers ... and cloned into an NL4.3 provirus backbone using the infusion homologous recombination method (Clontech Takara kit, Krakow, Poland). HIV-1 Gag-Pol infectious chimeric virus was packaged by transfection of 293T cells with pro-viral plasmids and titrated using a TZM-bl indicator cell assay, as described.

Rationale: Molecular cloning was used to generate chimeric infectious clones.

Answer: Yes
"""

"""
Question: 2601 

Evidence: Viral RNA was isolated from 140 µL plasma using a QIA-amp Viral RNA Mini Kit (Qiagen Inc, Valencia, CA, USA). 8--10 SGA amplicons were generated per patient and these were sequenced using di-deoxy sequencing technology (Applied Biosystems 3500).

Rationale: RNA for sequencing was obtained from plasma, indicating plasma virus sequencing.

Answer: Yes
"""

"""
Question: 2602 

Evidence: Viral RNA was isolated from 140 µL plasma using a QIA-amp Viral RNA Mini Kit (Qiagen Inc, Valencia, CA, USA). RNA was either frozen at −80 °C or immediately used to synthesize cDNA using SuperScript IV (Invitrogen, Ljubljana, Slovenia).

Rationale: The methods only describe plasma RNA extraction and sequencing; there is no mention of PBMC-derived sequencing.

Answer: No
"""

"""
Question: 2603 

Evidence: Thirty-two Ugandan protocol C participants had sequences successfully cloned from early samples drawn within 90 days of EDI and had their VRC characterized. Viral RNA was isolated from 140 µL plasma using a QIA-amp Viral RNA Mini Kit (Qiagen Inc, Valencia, CA, USA).

Rationale: The number of participants with sequenced plasma-derived viruses is 32.

Answer: 32
"""

"""
Question: 2604 

Evidence: Viral RNA was isolated from 140 µL plasma using a QIA-amp Viral RNA Mini Kit (Qiagen Inc, Valencia, CA, USA). RNA was either frozen at −80 °C or immediately used to synthesize cDNA using SuperScript IV (Invitrogen, Ljubljana, Slovenia).

Rationale: Only plasma-derived RNA sequencing is described; there is no report of PBMC virus sequencing.

Answer: 0
"""

"""
Question: 2605 

Evidence: Participants who became newly infected (tested positive for p24-antigen ELISA or HIV antibody) were invited to enroll. Viral RNA was isolated from 140 µL plasma using a QIA-amp Viral RNA Mini Kit (Qiagen Inc, Valencia, CA, USA).

Rationale: Sequencing was performed on plasma from newly infected individuals with detectable viremia/antigenemia, indicating active replication.

Answer: Yes
"""

"""
Question: 2606 

Evidence: Viral RNA was isolated from 140 µL plasma using a QIA-amp Viral RNA Mini Kit (Qiagen Inc, Valencia, CA, USA). RNA was either frozen at −80 °C or immediately used to synthesize cDNA using SuperScript IV (Invitrogen, Ljubljana, Slovenia).

Rationale: The study sequenced plasma RNA and not proviral DNA, so sequences were not obtained from the proviral reservoir.

Answer: No
"""

"""
Question: 2701 

Evidence: In this study, we documented the VRC supported by Gag-Pol gene chimeras with NL4.3 viruses generated from 32 Ugandan adults with very early HIV infection. Table 1 shows the participants' characteristics.

Rationale: The paper explicitly refers to adults and lists adult ages, indicating no infants/children.

Answer: No
"""

"""
Question: 2702 

Evidence: This was a laboratory-based study incorporated into a larger multi-center primary HIV-1 infection cohort (IAVI protocol C) through Clinical Research Centers in Uganda, Kenya, Rwanda, Zambia and South Africa. Participants who became newly infected (tested positive for p24-antigen ELISA or HIV antibody) were invited to enroll.

Rationale: The study is an observational cohort, not an interventional clinical trial.

Answer: No
"""

"""
Question: 2703 

Evidence: This was a laboratory-based study incorporated into a larger multi-center primary HIV-1 infection cohort (IAVI protocol C) through Clinical Research Centers in Uganda, Kenya, Rwanda, Zambia and South Africa. Participants who became newly infected (tested positive for p24-antigen ELISA or HIV antibody) were invited to enroll.

Rationale: Since it is a cohort study and not a clinical trial, not all individuals (indeed none) were in a clinical trial.

Answer: No
"""

"""
Question: 3101 

Evidence: Thirty-two Ugandan protocol C participants had sequences successfully cloned from early samples drawn within 90 days of EDI and had their VRC characterized. Table 1 shows the participants' characteristics.

Rationale: The number of individuals with sequenced samples is explicitly stated as 32.

Answer: 32
"""

"""
Question: 3102 

Evidence: Thirty-two Ugandan protocol C participants had sequences successfully cloned from early samples drawn within 90 days of EDI and had their VRC characterized. The Gag-Pol sequences described here have been deposited in GenBank with the accession numbers MT027065-MT027082, MW316895-MW316901, MW316906-MW316908, MW316914, MW316916, MW316920 and MW316924.

Rationale: All individuals discussed in the sequencing results are those 32 participants who had sequences obtained.

Answer: Yes
"""

"""
Question: 4101 

Evidence: Participants who became newly infected (tested positive for p24-antigen ELISA or HIV antibody) were invited to enroll. This study utilized protocol C stored plasma samples from 60 participants within 90 days post-EDI.

Rationale: Although early infection implies likely ART-naive status, the paper does not explicitly state ART exposure status; therefore this cannot be determined from the text alone.

Answer: NA
"""

"""
Question: 4102 

Evidence: This was a laboratory-based study incorporated into a larger multi-center primary HIV-1 infection cohort (IAVI protocol C). The paper describes sequencing and replication capacity analyses without reporting participants’ antiretroviral treatment histories.

Rationale: The study does not state whether any individuals had prior ARV exposure; thus it cannot be determined from the provided text.

Answer: NA
"""

"""
Question: 4103 

Evidence: This was a laboratory-based study incorporated into a larger multi-center primary HIV-1 infection cohort (IAVI protocol C). The paper does not report antiretroviral treatment histories for the sequenced individuals.

Rationale: Because ART status is not reported, there is no evidence that both ART-naive and ART-experienced groups were included.

Answer: No
"""

"""
Question: 4104 

Evidence: Participants who became newly infected (tested positive for p24-antigen ELISA or HIV antibody) were invited to enroll. The paper does not provide antiretroviral treatment histories for the sequenced individuals.

Rationale: Without explicit ART status, the number of ART-naive samples cannot be determined.

Answer: NA
"""

"""
Question: 4105 

Evidence: This was a laboratory-based study incorporated into a larger multi-center primary HIV-1 infection cohort (IAVI protocol C). The paper focuses on sequencing and replication capacity and does not detail antiretroviral treatment histories.

Rationale: No ART history information is presented for the individuals.

Answer: No
"""

"""
Question: 4201 

Evidence: We examined Ugandan viruses from newly infected patients and focused on the contribution of the Gag-Pol genes to replication capacity. VRC was measured using Gag-Pol chimeras of early virus Gag-Pol cloned into an NL4.3 clone backbone.

Rationale: The study does not analyze or report transmitted drug resistance prevalence.

Answer: No
"""

"""
Question: 4202 

Evidence: We examined Ugandan viruses from newly infected patients and focused on the contribution of the Gag-Pol genes to replication capacity. VRC was measured using Gag-Pol chimeras of early virus Gag-Pol cloned into an NL4.3 clone backbone.

Rationale: The paper does not report pretreatment drug resistance prevalence metrics.

Answer: No
"""

"""
Question: 4301 

Evidence: This was a laboratory-based study incorporated into a larger multi-center primary HIV-1 infection cohort (IAVI protocol C). The paper describes sequencing and replication capacity assays and does not report antiretroviral regimens received by participants.

Rationale: No antiretroviral drug class information is reported.

Answer: NA
"""

"""
Question: 4302 

Evidence: The paper focuses on viral sequencing and replication capacity assays and does not report antiretroviral regimens. The 13 domains from the HIV-1 Gag-Pol region are described by Pfam, and preliminary results showed that seven domains ... showed variation in the set of 32 sequences.

Rationale: There is no report of integrase inhibitor usage among participants.

Answer: No
"""

"""
Question: 4303 

Evidence: The paper focuses on viral sequencing and replication capacity assays and does not report antiretroviral regimens. VRC was measured using Gag-Pol chimeras of early virus Gag-Pol cloned into an NL4.3 clone backbone.

Rationale: There is no report of protease inhibitor usage among participants.

Answer: No
"""

"""
Question: 4304 

Evidence: This was a laboratory-based study incorporated into a larger multi-center primary HIV-1 infection cohort (IAVI protocol C). The paper does not report antiretroviral treatment histories or regimens.

Rationale: No ART information is provided, so it cannot be determined whether all individuals received the same ART.

Answer: NA
"""

"""
Question: 4305 

Evidence: The paper does not report antiretroviral treatment histories or regimens. Participants who became newly infected (tested positive for p24-antigen ELISA or HIV antibody) were invited to enroll.

Rationale: INSTI exposure status is not reported; therefore, INSTI-naivety cannot be determined.

Answer: NA
"""

"""
Question: 4403 

Evidence: The paper does not report antiretroviral treatment histories or regimens. This was a laboratory-based study incorporated into a larger multi-center primary HIV-1 infection cohort (IAVI protocol C).

Rationale: Without ART regimen data, the number of individuals with more than one regimen cannot be determined.

Answer: NA
"""

"""
Question: 4404 

Evidence: The paper does not report antiretroviral treatment histories or regimens. This was a laboratory-based study incorporated into a larger multi-center primary HIV-1 infection cohort (IAVI protocol C).

Rationale: Without ART regimen data, the number of individuals with more than two regimens cannot be determined.

Answer: NA
"""

"""
Question: 4405 

Evidence: The paper does not report antiretroviral treatment histories or regimens. VRC was measured using Gag-Pol chimeras of early virus Gag-Pol cloned into an NL4.3 clone backbone.

Rationale: Since ART histories are not provided, we cannot assess whether individuals received the same number of regimens.

Answer: NA
"""

"""
Question: 4406 

Evidence: The paper does not report antiretroviral treatment histories or regimens. This study utilized protocol C stored plasma samples from 60 participants within 90 days post-EDI.

Rationale: No ART data are reported, so we cannot conclude that all individuals received one regimen.

Answer: NA
"""

"""
Question: 4501 

Evidence: The paper does not report antiretroviral treatment histories or specific drugs received. The study focuses on sequencing and replication capacity.

Rationale: Without ART data, the number who received dolutegravir cannot be determined.

Answer: NA
"""

"""
Question: 4502 

Evidence: The paper does not report antiretroviral treatment histories or specific drugs received. The study focuses on sequencing and replication capacity.

Rationale: Without ART data, the number who received darunavir cannot be determined.

Answer: NA
"""

"""
Question: 5101 

Evidence: The paper does not analyze drug resistance mutations or report prevalence. Using a novel protein domain approach, we then documented diversity in the functional protein domains across the Gag-Pol region and identified differences in the Gag-p6 domain that were frequently associated with higher in vitro replication.

Rationale: No resistance mutation analyses were presented; therefore counts cannot be determined.

Answer: NA
"""

"""
Question: 5102 

Evidence: The paper does not analyze drug resistance mutations or report prevalence. The 13 domains from the HIV-1 Gag-Pol region are described by Pfam, and preliminary results showed that seven domains ... showed variation in the set of 32 sequences.

Rationale: No INSTI-resistance mutation data are reported.

Answer: NA
"""

"""
Question: 5103 

Evidence: The paper does not analyze drug resistance mutations or report prevalence. VRC was measured using Gag-Pol chimeras ... relative to wildtype NL4.3.

Rationale: No TDF-resistance mutation data are reported.

Answer: NA
"""

"""
Question: 5104 

Evidence: The paper does not analyze drug resistance mutations or report prevalence. The focus was on replication capacity and domain variation, particularly in Gag-p6.

Rationale: No INSTI-resistance mutations were reported.

Answer: NA
"""

"""
Question: 6101 

Evidence: To assess the VRC of Gag-Pol NL4.3 chimeras, 5 × 10^5 GXR25 cells were infected at a multiplicity of infection (MOI) of 0.05. Replication capacity values were generated by dividing the area under the curve (AUC) for days 2--6 of the chimeric viruses by the AUC of the NL4.3 wildtype after subtracting the negative control.

Rationale: The paper conducted replication capacity assays, not phenotypic drug susceptibility tests; thus no phenotypic susceptibility method is reported.

Answer: NA
"""

"""
Question: 6102 

Evidence: Replication capacity values were generated by dividing the area under the curve (AUC) for days 2--6 of the chimeric viruses by the AUC of the NL4.3 wildtype after subtracting the negative control. The absorbance of the samples was determined using a microplate (ELISA) reader and was directly correlated to the level of RT activity in the sample using the manufacturer's instructions.

Rationale: The study reports AUC-based replication measures and RT activity; no IC50/IC90 values are presented.

Answer: No
"""

"""
Question: 6103 

Evidence: Replication capacity values were generated by dividing the area under the curve (AUC) for days 2--6 of the chimeric viruses by the AUC of the NL4.3 wildtype after subtracting the negative control. VRC was measured using Gag-Pol chimeras of early virus Gag-Pol cloned into an NL4.3 clone backbone.

Rationale: The study does not present IC50 fold change metrics; it focuses on replication capacity normalized to NL4.3.

Answer: No
"""

"""
Question: 6104 

Evidence: The paper describes replication capacity assays of chimeric viruses and quantification by reverse transcriptase activity and ELISA-based colorimetric readout. VRC was measured using Gag-Pol chimeras of early virus Gag-Pol cloned into an NL4.3 clone backbone.

Rationale: No phenotypic drug susceptibility assay was used or reported.

Answer: NA
"""

"""
Question: 6105 

Evidence: VRC was measured using Gag-Pol chimeras of early virus Gag-Pol cloned into an NL4.3 clone backbone. Replication capacity values were generated by dividing the area under the curve (AUC) for days 2--6 of the chimeric viruses by the AUC of the NL4.3 wildtype after subtracting the negative control.

Rationale: The paper explicitly measures and reports replication capacity.

Answer: Yes
"""

"""
Question: 6106 

Evidence: The study assessed replication capacity without testing antiretroviral drug susceptibility. Replication capacity values were generated by dividing the area under the curve (AUC) ... relative to wildtype NL4.3.

Rationale: No drugs were tested in phenotypic susceptibility assays; therefore none can be listed.

Answer: NA
"""

"""
Question: 7101 

Evidence: A panel of Gag-Pol sequences generated using single genome amplification from incident HIV-1 infections were cloned into a common HIV-1 NL4.3 pol/env backbone. The Gag-Pol amplicons were re-amplified ... and cloned into an NL4.3 provirus backbone using the infusion homologous recombination method.

Rationale: The isolates were patient-derived chimeras; no site-directed mutagenesis was performed.

Answer: No
"""

"""
Question: 7102 

Evidence: We examined Ugandan viruses from newly infected patients and focused on the contribution of the Gag-Pol genes to replication capacity. To assess the VRC of Gag-Pol NL4.3 chimeras, 5 × 10^5 GXR25 cells were infected ... and viral supernatants were collected through day 10.

Rationale: The viruses were derived from clinical samples and tested in short-term replication assays; there were no serial in vitro passage experiments to derive isolates.

Answer: No
"""